Fecal Microbiota Transplantation for IBS
Irritable Bowel Syndrome, Diarrhea
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome focused on measuring Post-infection irritable bowel syndrome with diarrheal, Post-infection irritable bowel syndrome with mixed symptoms
Eligibility Criteria
Inclusion Criteria: Campylobacter PI-IBS defined by Rome III or Rome IV criteria Non IBS-C Moderate to severe symptoms defined by IBS-SSS≥175 Able to safely undergo and consent to colonoscopy Exclusion Criteria Immune deficiency or treatment with immunosuppressive medications Severe bowel or medical disease precluding administration of bowel prep Severe bowel or medical disease precluding colonoscopy with conscious sedation Active cancer Pregnant or lactating Abdominal surgery (exception of fundoplication, hernia, appendectomy, cholecystectomy, caesarean section and hysterectomy) Severe psychiatric disorder (HADS-A or D>16), or diagnosed alcohol or drug abuse disorder New probiotics or treatment with antibiotics, NSAIDs (within 4 wks prior to study entry) Use of treatments known to affect colonic motility (with exception of loperamide) Diagnosed h/o bleeding disorder Organic GI diseases (IBD, celiac disease, microscopic colitis) Chronic kidney or liver disease Absolute neutrophil count (ANC) <500 IU/ml
Sites / Locations
- Mayo Clinic in Minnesota
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Donor Fecal Microbiota Transplantation Group
Autologous Fecal Microbiota Transplantation Group
Subjects will receive a fecal microbiota transplantation (FMT) using stool from a donor
Subjects will receive a fecal microbiota transplantation (FMT) using their own stool